Detalhe da pesquisa
1.
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Ann Oncol
; 25(9): 1762-1769, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25122671
2.
Rationale and design of a UK database for a rare cancer type: the GEM Registry for gastrointestinal stromal tumours.
Br J Cancer
; 109(6): 1403-7, 2013 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23963143
3.
Correspondence Re: C. Caserini et al., Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clin. Cancer Res., 3: 955-961, 1997.
Clin Cancer Res
; 4(1): 261-2, 1998 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-9516980
4.
Irinotecan and 5-fluorouracil in colorectal cancer: time for a pause?
Eur J Cancer
; 34(3): 286-9, 1998 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-9640211
5.
Paclitaxel in recurrent ovarian cancer: better upfront? Comments on: A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study. Eur J Cancer 1977, 33, 160-163.
Eur J Cancer
; 33(11): 1905-6, 1997 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-9470858
6.
A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec).
Int J Surg
; 3(3): 206-12, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-17462285
7.
Paclitaxel in advanced ovarian cancer: too much optimism?
Gynecol Oncol
; 66(2): 335-6, 1997 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-9264587